Add BrightSurf on Google Email

Biology in four dimensions

Scientists at EMBL have developed a new model for protein-complex interactions in yeast, revealing that key components are produced ahead of time and assembled as needed. This discovery sheds light on the dynamic behavior of cellular machines and offers potential applications in studying human and animal biological systems.

Emory biochemist writes lead essay describing Nobel Prize research on ubiquitin protein

Dr. Keith Wilkinson's Nobel Prize-winning research on ubiquitin has provided detailed information about cell survival and death, shedding light on the ubiquitin system's role in regulating protein turnover rates. The discoveries present opportunities to develop highly selective drugs targeting various aspects of the ubiquitin pathway.

A new twist on the mad cow

Researchers at Scripps Research Institute find normal cellular prion protein essential for prion diseases like BSE, and inducing neurotoxicity without scrapie prions triggers catastrophic outcomes. This discovery highlights the complexity of prion pathogenesis and challenges existing therapeutic approaches.

SourceScripps Research Institute·JournalScience·DateJan 29, 2004

'Suicide proteins' contribute to sperm creation

Researchers found that multiple caspases and regulators are required for proper sperm formation in fruitflies, highlighting a non-apoptotic process. This discovery could provide insights into male infertility and suggest possible treatments.

SourcePLOS·JournalPLOS Biology·DateDec 15, 2003

UC Irvine molecular biologists discover key protein interaction that stabilizes cholesterol levels in cells

UC Irvine molecular biologists have discovered a key protein interaction that regulates cholesterol levels in cells, which may provide insights into heart disease and stroke prevention. The study found that a regulatory protein called Sp1 recruits a co-regulating protein to activate genes that balance cholesterol levels.

SourceUniversity of California - Irvine·JournalProceedings of the National Academy of Sciences·DateJun 6, 2000

New protein separation technology

Researchers have created a new liquid-phase protein separation technology that can help scientists solve the proteomics puzzle. The system eliminates time-consuming 2-D gel electrophoresis and can detect trace amounts of protein, providing valuable insights into cancer research and other areas of science.

SourceUniversity of Michigan·JournalAnalytical Chemistry·DateApr 17, 2000

Understanding key protein in Fragile X syndrome

Researchers identified three key molecular actors involved in Fragile X syndrome, including the protein FMRP, which binds to messenger RNA molecules and regulates translation. The study sheds light on the cellular mechanisms underlying the disorder, potentially leading to new treatments for other types of mental retardation.

SourceHoward Hughes Medical Institute·JournalMolecular and Cellular Biology·DateNov 29, 1999

Research puts sting into drama of virus-cell fusion

Researchers at Purdue University have identified a protein segment crucial for the infection of cells by retroviruses and other viruses. By replacing just one amino acid in this region, they were able to eliminate fusion between the virus and its host cell. This discovery may lead to novel treatments to block the entry of these viruses.

SourcePurdue University·JournalMolecular Biology of the Cell·DateSep 1, 1999

New anti-angiogenic proteins discovered

Researchers at UCLA and Human Genome Sciences have discovered two human proteins, METH-1 and METH-2, that inhibit blood vessel formation and show promise in treating a range of cancer tumors. The proteins were found to be more potent than endostatin in preventing new blood vessel growth.

SourceHuman Genome Sciences, Inc.·JournalJournal of Biological Chemistry·DateAug 5, 1999

Common antibiotic could treat some Duchenne muscular dystrophy patients - Other genetic diseases might yield to similar strategy

Researchers found that a common antibiotic, gentamicin, can arrest disease progression in 15% of Duchenne muscular dystrophy patients with a specific genetic mutation. The approach may also be effective for similar subsets of people with other genetic disorders. Small-scale clinical trials are planned to test the treatment.

SourceUniversity of Pennsylvania School of Medicine·JournalJournal of Clinical Investigation·DateJul 30, 1999